Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01578460
Other study ID # R-11-223
Secondary ID 17686
Status Completed
Phase N/A
First received April 5, 2012
Last updated March 9, 2017
Start date May 2012
Est. completion date August 29, 2014

Study information

Verified date March 2017
Source Lawson Health Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Poor glucose control during pregnancy is a significant concern for Canadian women with diabetes. This problem is magnified in First Nations women, who have among the highest rates of gestational diabetes (GDM) in the world (up to 18% of First Nations women will develop GDM during pregnancy and 70% of these will go on to develop type 2 diabetes later). Continuous glucose monitoring (CGM) technology has the potential to help women maintain tighter control during pregnancy, however, in the First Nations population, there are many unique barriers that may affect use of this technology. Such barriers include remoteness of the community, cultural apprehension, lack or difficulty of access to care, and language differences.

A total of 60 participants from three participating First Nations communities in Southern Ontario will participate in the study. Participants will self-select to either the CGM group (n=30) or the control group (n=30) after consenting to participate in the study. Participants in both groups will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation. Primary outcomes to be evaluated include maternal A1c and offspring birth weight. To assess the feasibility and acceptability of CGMs among First Nations women, a questionnaire will be distributed to participants to gather insight into their rationale for enrolling into either group. Recruitment rates for both groups will also be used to assess feasibility and acceptability of CGMs. Additionally, all participants will be encouraged to participate in a community lifestyle program consisting of 30-min exercise sessions offered five days a week. The community lifestyle program will be adapted to the community, linked to existing programs with support from program personnel and will include educational sessions related to diabetes and healthy lifestyles. It is hypothesized that through participation in the community lifestyle program, pregnant First Nations women with diabetes will experience a decrease in their blood glucose values post-exercise, mitigate excessive weight gain and normalize their A1c's. It is further hypothesized that an increase in women's regular physical activity levels, the number of steps taken and knowledge of diabetes will be observed.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date August 29, 2014
Est. primary completion date August 29, 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- First Nations (self-identified)

- On-reserve (living or receiving care)

- Informed consent to participate

- Adults aged 18 years or older

- Diagnosed with gestational diabetes (GDM) or type 2 diabetes (T2DM)

- Pregnant (less than or equal to 36 weeks o gestation)

- Consent to have primary care giver informed of participation in teh project

- Willingness to perform required study and data collectin procedures and adhere to the operating requirements of the iPro2 and/or the glucose meter

- Willingness to wear the iPro 2 continuous glucose monitor (CGM) for 5 days for the 28th, 32nd, 36th week of pregnancy (for participants in the CGM group)

- Willingness to perform at least 4 finger prick testing per day during the Monitoring Week of the 28th, 32nd, 36th week of pregnancy (for CGM and control group)

Exclusion Criteria:

- Lack of decision making capacity to provide consent

- Participating in another diabetes and/or lifestyle improvement research project

- Non-First Nations descent

- Pregnant diagnosed with type 1 diabetes

- Pregnant not diagnosed with GDM or T2DM

- Pregnant women past 36th week of gestation

- Participants who do not consent to have their primary care giver informed of project participation

- The participant has a history of tape allergies that have not been resolved

- The participant has any skin abnormality (e.g. Psoriasis, rash, staphylococcus infection) that has not been resolved and would inhibit her from wearing the sensor

- Any other condition (s) that in the Investigator's opinion would warrant exclusion from the study or prevent the participant from completing the project

Study Design


Intervention

Device:
Continuous Glucose Monitoring
Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.
Glucose Meter
Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.

Locations

Country Name City State
Canada Western University London Ontario

Sponsors (2)

Lead Sponsor Collaborator
Stewart Harris Juvenile Diabetes Research Foundation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maternal HbA1c Lab collected at the specific time periods listed above. 24, 28, 32 and 36th week of gestation. This will occur between May 2012 to September 2014
Primary Offspring Birth Weight Offspring birth weight will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. At Delivery. This will occur between May 2012 to September 2014.
Secondary 1 hour post-prandial glucose measurements (maternal) This will be collected from the CGM or glucose meter, depending on the group the participant consents to take part in. 28, 32 and 36th week of gestation. This will occur between May 2012 to September 2014.
Secondary Weight gain (maternal) Baseline weight is collected from Antenatal Record 1 and 2 (Ontario Ministry of Health and Long-Term Care forms). Follow-up weight measurements are done at each visit until delivery. Weight gain is calculated from the baseline and follow-up measurements. Weight is recorded at each visit from May 2012 to September 2014.
Secondary Maternal diabetes treatment Baseline treatment will be collected from Antenatal Record 1 and 2 (Ontario Ministry of Health and Long-Term Care forms) if available. 28, 32, and 36 weeks of gestation. This will occur between May 2012 to September 2014.
Secondary Daily mean glucose values (maternal) This will be calculated from the glucose measurements taken using either the CGM or the glucose meter. 28, 32 and 36th week of gestation. This will occur between May 2012 to September 2014.
Secondary Insulin Use (maternal) Baseline insulin use will be collected from Antenatal Record 1 and 2 (Ontario Ministry of Health and Long-Term Care forms) if available. 24, 28, 32, and 36 weeks of gestation. This will occur between May 2012 to September 2014.
Secondary Neonatal gestational age Neonatal gestational age will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. At Delivery. This will occur between May 2012 to September 2014.
Secondary Neonatal hypoglycemia Neonatal hypoglycemia will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. At Delivery. This will occur between May 2012 to September 2013.
Secondary Neonatal Intensive Care Unit (NICU) Admission This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. At Delivery. This will occur between May 2012 to September 2014.
Secondary Number of days in the hospital (neonatal) This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. At Delivery. This will occur between May 2012 to September 2014.
Secondary Birth injuries (neonatal) This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. At Delivery. This will occur between May 2012 to September 2014.
Secondary Jaundice (neonatal) This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. At Delivery. This will occur between May 2012 to September 2014.
Secondary Delivery in a community or teaching hospital This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. At Delivery. This will occur between May 2012 to September 2014.
Secondary Caesarean section rate (maternal) This will be collected from the Neonatal Examination Form/Birth Record and Maternal Discharge Summary. At Delivery. This will occur between May 2012 to September 2014.
Secondary Delivery Methods Forceps, vacuum-assisted. This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. At Delivery. This will occur between May 2012 to September 2014.
Secondary Cephalopelvic disproportion This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. At Delivery. This will occur between May 2012 to September 2014.
Secondary Number of days in hospital post delivery (maternal) This will be collected from the Maternal Discharge Summary. At Delivery. This will occur between May 2012 to September 2014.
Secondary Shoulder Dystocia (neonatal) This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. At Delivery. This will occur between May 2012 to September 2014.
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02226003 - Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) Phase 3